Full-Time

Biostatistics Director

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$226.4k - $257k/yr

Belmont, MA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
SAS
R
Biostatistics

Get referred to Treeline Biosciences

See people who can refer or advise you

Requirements
  • Ph.D. in Biostatistics or Statistics with 6+ years of biotech/pharma experience, OR MS in Biostatistics or Statistics with 8+ years of biotech/pharma experience.
  • Minimum of 3 years of hands-on experience designing, modeling, and analyzing early-phase oncology trials (Phase I/II).
  • Proven track record of taking individual oncology trials from protocol design through final CSR.
  • Advanced, hands-on programming expertise in R and SAS (specifically for trial simulations, complex oncology datasets, and visualization packages like Shiny).
  • Expert knowledge of early oncology endpoints (e.g., DLT, PFS, ORR, RECIST 1.1, Lugano criteria).
  • Comfort working in a fast-paced environment with a high volume of early-stage data iterations.
  • Outstanding written and verbal communication skills, with a proven ability to influence matrixed teams and explain statistical concepts simply.
Responsibilities
  • Lead the statistical design and execution of individual oncology protocols, including sample size calculations, randomization schemes, and adaptive design simulations.
  • Implement and execute trial-level dose-finding methodologies, such as Bayesian Optimal Interval (BOIN), and cohort expansion models.
  • Program, validate, and perform statistical analyses for trial data cuts, Safety Review Committees, and Dose Escalation Meetings.
  • Author trial-specific Statistical Analysis Plans, design shell tables, listings, and figures (TLFs), and write statistical sections of Clinical Study Reports (CSRs).
  • Design and build dynamic data visualizations, dashboards, and interactive graphics (e.g., using R/Shiny) to track real-time dose escalation, safety signals, and biomarker trends.
  • Translate complex statistical outputs and trial models into intuitive, high-impact visual decks for executive leadership, investors, and scientific advisory boards.
  • CRO Management: Provide direct technical oversight to CRO programmers and biostatisticians, verifying all trial-level deliverables for quality and accuracy.
  • Regulatory Submissions: Prepare data packages and statistical rationales for Investigational New Drug (IND) submissions and expedited regulatory filings.
  • Study Teams: Serve as the core biostatistician on clinical trial working groups, collaborating daily with Clinical Leads, Data Managers, and Biomarker scientists.
  • Data Integration: Blend pharmacokinetic (PK/PD) and translational biomarker data into trial-level exploratory analyses to identify early safety or efficacy signals.

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Get referred to Treeline Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Treeline started three Phase 1 trials and planned a fourth in 2026.
  • The company closed a $200 million extension, reaching $1.1 billion total funding.
  • FTC early terminated HSR review on July 21, 2026, easing merger timing.

What critics are saying

  • The reverse-merger structure triggered shareholder investigations in June 2026 over fairness.
  • Treeline still lacks approved products; Phase 1 oncology data remains unproven.
  • If TLN-121, TLN-254, and TLN-372 disappoint, Treeline becomes a cash-burning shell.

What makes Treeline Biosciences unique

  • Josh Bilenker and Jeff Engelman built Treeline from Loxo Oncology experience.
  • Treeline advanced three Phase 1 oncology programs by September 2025.
  • The June 2026 Standard BioTools merger brings over $900 million pro forma cash.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

1%
My Malone Telegram
Jun 19th, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN)...

BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN), Standard BioTools Inc. (Nasdaq - LAB). * Jun 19, 2026 BALA CYNWYD, Pa., June 19, 2026 (GLOBE NEWSWIRE) - Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. AstroNova, Inc. (Nasdaq - ALOT) Under the terms of the Merger Agreement, AstroNova will be acquired by Arcline Investment Management for $29.00 per share in cash in an all-cash transaction with a total enterprise value of approximately $272 million. The investigation concerns whether the AstroNova Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Open Lending Corporation (Nasdaq - LPRO) Under the terms of the Merger Agreement, Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share. The investigation concerns whether the Open Lending Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Huntsman Corporation (NYSE - HUN) Under the terms of the Merger Agreement, Huntsman will be acquired by Olin Corporation (NYSE - OLN) whereby Huntsman shareholders will receive 0.5476 shares in Olin for every one (1) share of Huntsman. Upon completion of the transaction, Olin shareholders will own approximately 54.5% and Huntsman shareholders will own approximately 45.5% of the combined company. The investigation concerns whether the Huntsman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Standard BioTools Inc. (Nasdaq - LAB) Under the terms of the Merger Agreement, Standard BioTools will be acquired by Treeline Biosciences, Inc. At the closing of the proposed combination, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company. The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Endpoints News
Jun 8th, 2026
Treeline to go public via reverse merger with Standard BioTools.

Treeline to go public via reverse merger with Standard BioTools. News reporter. Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

GlobeNewswire
Jun 8th, 2026
Standard BioTools and Treeline Biosciences Announce Merger Agreement

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy...

Endpoints News
Sep 3rd, 2025
Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.

Business Wire
Sep 3rd, 2025
Treeline Biosciences Secures $200M, Starts Trials

Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.